The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 6 May 2026•Updated 6 May 2026•

1 min read

Protagonist Therapeutics Delivers Massive Earnings Beat with Surprise Profit

Key Facts

1Protagonist Therapeutics reported an EPS of $0.05, beating analyst consensus estimates of ($0.65) by $0.70.

2The company's revenue reached $56.37 million, far surpassing the $12.21 million expected.

28 days ago

Version History

Version 128 days ago

What changed: Added Citizens Jmp's new $137.00 price target, quantified insider sales at $15 million, and noted the rise in institutional ownership to 98.63%.

Protagonist Therapeutics reported a significant earnings beat, posting a surprise profit of $0.05 per share against an expected loss of $0.65. This performance, driven by revenue of $56.37 million, led Citizens Jmp to set a new price target of $137.00 for the stock. However, market caution persists as insider sales have exceeded $15 million over the past 90 days. Despite these sales, institutional confidence remains exceptionally high, with institutional ownership reaching 98.63%. Investors are now focused on whether the company can maintain this momentum and achieve sustained profitability. This combination of strong earnings and high institutional backing marks a pivotal phase for the biotechnology firm's market valuation.